Clinical Trials 

At the Houston Methodist Kenneth R. Peak Brain and Pituitary Tumor Treatment and Research Center, we offer aggressive treatment and access to research studies in the management of brain cancer. Examples of potential research studies include gene therapy, immune therapy and the use of personalized tumor vaccines made from tumor tissue obtained during surgery. The results from these research studies may affect future clinical alternatives for all patients. A brief description of our most promising trials follows.


This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM). This study is comprised of newly diagnosed patients with AA or GBM. The intention is to treat all patients with the standard of care chemotherapy with temozolomide using the Stupp protocol and radiation therapy as well as with HSV-tk + valacyclovir gene therapy with a single dose administered intra-operatively at the time of tumor resection. Read more >


This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma multiforme. This study is comprised of patients who have failed initial standard of care treatment (maximal safe resection followed by chemoradiation) and whose tumors have recurred. Read more >


P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5)

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Read more >


A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (NCT03149003)

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. Read more >


NWBT 020221 - DC-Vax

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo.  Read more >


A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 S-apr) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery.

The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery (NCT02891070). Read more >


For more information, please contact us at: 713.441.8500

Kenneth R. Peak Research Center